UK to offer alternatives to AstraZeneca jab for under-30s

LONDON: Britain on Wednesday said it would adopt new medical advice to offer most people under 30 an alternative to the AstraZeneca coronavirus jab if possible, due to concerns over blood clots.

A potential blow to the United Kingdom’s highly successful Covid-19 vaccine program, it comes after the country’s medicines regulator reassessed the shot’s safety following dozens of clotting incidents among people who had received it.

The MHRA regulator said its “rigorous scientific review of all available data” had found 79 blood clots and 19 deaths among people who had received one of the 20 million AstraZeneca doses administered in the UK.

It insisted such incidents remained “extremely rare.”

The European Medicines Agency said earlier that clots should be listed as a “very rare” side effect of the vaccine. Both bodies however said that it should still be used, as the dangers from catching coronavirus were greater than those of receiving the jab.

AstraZeneca released a statement saying that the two studies “reaffirmed” that the benefits of its vaccine “far outweigh the risks.”

But Britain’s Joint Committee on Vaccination and Immunization (JCVI), which advises the government, said that given the lower risk posed by the virus to young people, it would change its guidance for them.

“Adults who are aged 18 to 29 years old who do not have an underlying health condition… should be offered an alternative Covid-19 vaccine in preference to the AstraZeneca vaccine,” Wei Shen Lim of the JCVI told journalists.

The alternatives, which in Britain currently are vaccines developed by US firm Moderna and Pfizer-BioNTech, should be offered “if available”, he said.

AstraZeneca said in its statement that it was “already working to understand the individual cases, epidemiology and possible mechanisms that could explain these extremely rare events.”

‘Full confidence’

Britain has administered nearly 32 million first vaccine doses to people — around 60 percent of the adult population — in one of the world’s most successful inoculation drives.

But the country has relied heavily on the AstraZeneca shot, developed in partnership with Oxford University.

It has faced a host of issues in Europe and beyond since it began to be rolled out in the UK in early December.

Despite the setbacks, Oxford University’s Andrew Pollard said Wednesday, that the vaccine developers would “continue with our mission to support global vaccination, not for profit, for the benefit of humanity.”

Prime Minister Boris Johnson welcomed the latest reviews and new guidance from the JCVI. The vaccine is “safe, effective and has already saved thousands of lives”, he said.

“We will follow today’s updated advice, which should allow people of all ages to continue to have full confidence in vaccines, helping us save lives and cautiously return towards normality,” he said on Twitter.

He also said that he saw no reason to deviate from his plans to take the country out of lockdown, which were based on vaccinating all adults by the end of July. “We’re very secure about our supply,” he added.

England’s deputy chief medical officer Jonathan Van-Tam described the new advice as “a course correction” in the vaccine drive.

“There’s no question about that, but it is in a sense, in medicine, quite normal for physicians to alter their preferences for how patients are treated over time,” he said.

First Moderna jab

The developments came as the UK began rolling out the first of 17 million Moderna vaccines ordered, its third approved jab and one which is already being delivered elsewhere in Europe and in the United States.

The first shot of the two-stage Moderna inoculation was given at a hospital in Wales to 24-year-old Elle Taylor.

“I’m an unpaid carer for my grandmother so it is very important to me that I get it, so I can care for her properly and safely,” she told reporters.

Taylor said she would have been happy to take the AstraZeneca jab despite the adverse publicity about blood clots.

The arrival of the Moderna inoculation represents a timely diversification of Britain’s vaccine rollout, with AstraZeneca hit by supply problems as well as the clot controversy.